secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2026-09-14T20:04:48+00:00
Accession:  0001193125-26-390539
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec FY2026 net loss $45.5M; BB-301 cohorts complete follow-up, FDA meeting held
--------------------------------------------------------------------------------

- FY2026 net loss attributable to shareholders was $45.5M ($0.98/share), vs $37.9M ($1.05/share) in FY2025.
- Total expenses rose to $51.2M from $41.8M; R&D up to $23.4M, G&A up to $27.8M.
- Cash and equivalents $180.0M at June 30, 2026.
- All six Cohort 1 low-dose BB-301 patients completed 12-month follow-up; Cohort 2 fully enrolled, all treated safely.
- Type C FDA meeting held in 3Q2026 on BB-301 pivotal design; minutes expected in October; pivotal trial init planned mid-2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312526390539/0001193125-26-390539-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312526390539/bntc-20260914.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-390539

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer